Does Medical Mutual Cover Weight Loss Medication? The 2026 Policy Breakdown and What to Do When Coverage Is Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medical Mutual covers FDA-approved GLP-1 medications (Wegovy, Zepbound, Saxenda) for weight loss only when BMI is 30+ or 27+ with comorbidities, and only after prior authorization approval
• Ozempic and Mounjaro are covered for diabetes but not for off-label weight loss under most Medical Mutual plans as of April 2026
• Prior authorization requires documented diet and exercise failure, specific BMI thresholds, and provider attestation, with average approval time of 7 to 14 business days
• Compounded semaglutide and tirzepatide are not covered by Medical Mutual or any major insurer, but cost $297 to $347 per month through FormBlends compared to $1,000+ for brand-name medications without coverage

Direct answer (40-60 words)

Medical Mutual covers FDA-approved weight loss medications including Wegovy, Zepbound, and Saxenda under medical necessity criteria. Coverage requires BMI of 30 or higher (or 27+ with weight-related comorbidities), prior authorization approval, and documented failure of diet and exercise. Ozempic and Mounjaro are covered only for diabetes treatment, not weight loss. Compounded versions are never covered.

Table of contents

1. The current Medical Mutual weight loss medication policy (2026)
2. Which medications are covered vs excluded
3. The BMI and comorbidity requirements that determine eligibility
4. The prior authorization process: step-by-step protocol
5. What most articles get wrong about "diabetes-only" coverage
6. Average approval times and denial rates from internal data
7. The three failure modes of Medical Mutual prior authorization
8. When Medical Mutual denies coverage: the appeal protocol
9. Cost comparison: covered brand-name vs compounded alternatives
10. The employer plan variable: why your specific coverage may differ
11. Clinical patterns: what we see in authorization success rates
12. FAQ
13. Sources
14. Footer disclaimers

The current Medical Mutual weight loss medication policy (2026)

Medical Mutual of Ohio, one of the largest health insurers in the state with approximately 1.6 million members, updated its weight management medication policy in January 2026. The policy distinguishes between FDA-approved anti-obesity medications and diabetes medications used off-label for weight loss.

The core policy framework:

Covered medications for weight loss (with prior authorization):

• Wegovy (semaglutide 2.4 mg weekly injection)
• Zepbound (tirzepatide 2.5 to 15 mg weekly injection)
• Saxenda (liraglutide 3 mg daily injection)
• Contrave (naltrexone/bupropion combination)
• Qsymia (phentermine/topiramate combination)

Not covered for weight loss (diabetes indication only):

• Ozempic (semaglutide 0.25 to 2 mg weekly)
• Mounjaro (tirzepatide 2.5 to 15 mg weekly)
• Rybelsus (oral semaglutide)
• Victoza (liraglutide 0.6 to 1.8 mg daily)

Never covered:

• Compounded semaglutide
• Compounded tirzepatide
• Any non-FDA-approved formulation
• Medications obtained through telehealth platforms without Medical Mutual network participation

The distinction between Wegovy and Ozempic (both semaglutide) or Zepbound and Mounjaro (both tirzepatide) is purely regulatory. The FDA approved Wegovy and Zepbound specifically for chronic weight management. Ozempic and Mounjaro carry only diabetes indications. Medical Mutual's policy follows FDA labeling exactly.

This creates a coverage paradox: identical active ingredients, different brand names, different coverage. A patient prescribed Ozempic 2 mg for weight loss will face denial. The same patient prescribed Wegovy 2.4 mg will likely get approval if they meet medical necessity criteria.

Which medications are covered vs excluded

The table below shows Medical Mutual's 2026 coverage status for all major weight loss medications:

Medication	Active ingredient	FDA indication	Medical Mutual coverage	Prior auth required	Typical copay (Tier 3)
Wegovy	Semaglutide 2.4 mg	Weight loss	Yes	Yes	$50-$150
Zepbound	Tirzepatide	Weight loss	Yes	Yes	$50-$150
Saxenda	Liraglutide 3 mg	Weight loss	Yes	Yes	$50-$100
Ozempic	Semaglutide 0.5-2 mg	Diabetes only	No (for weight loss)	N/A	Covered only for diabetes
Mounjaro	Tirzepatide	Diabetes only	No (for weight loss)	N/A	Covered only for diabetes
Contrave	Naltrexone/bupropion	Weight loss	Yes	Yes	$30-$75
Qsymia	Phentermine/topiramate	Weight loss	Yes	Yes	$30-$75
Phentermine (generic)	Phentermine	Short-term weight loss	Yes	Sometimes	$10-$30
Compounded semaglutide	Semaglutide (compounded)	None (not FDA-approved)	No	N/A	Not applicable
Compounded tirzepatide	Tirzepatide (compounded)	None (not FDA-approved)	No	N/A	Not applicable

Copay amounts vary by specific Medical Mutual plan tier. The figures above represent the most common employer-sponsored plans. High-deductible health plans (HDHPs) may require full cost until the deductible is met, which can be $1,349 per month for Wegovy or $1,060 per month for Zepbound at retail pricing.

The BMI and comorbidity requirements that determine eligibility

Medical Mutual's medical necessity criteria for weight loss medication coverage follow the 2026 American Association of Clinical Endocrinology (AACE) guidelines with minor modifications. The requirements are:

Primary criterion (must meet one):

• BMI of 30 kg/m² or greater, OR
• BMI of 27 kg/m² or greater with at least one weight-related comorbidity

Qualifying comorbidities:

• Type 2 diabetes (HbA1c 5.7% or higher, or documented diagnosis)
• Hypertension (BP 130/80 or higher, or on antihypertensive medication)
• Dyslipidemia (LDL 130 mg/dL or higher, triglycerides 150 mg/dL or higher, or on statin therapy)
• Obstructive sleep apnea (documented by sleep study)
• Non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH)
• Cardiovascular disease (prior MI, stroke, or documented coronary artery disease)
• Polycystic ovary syndrome (PCOS) with documented metabolic dysfunction

Additional requirements:

• Documented failure of diet and exercise for at least 6 months
• Provider attestation that patient has attempted behavioral weight loss interventions
• No contraindications to GLP-1 therapy (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, history of pancreatitis)

The 6-month diet and exercise documentation requirement is the most common reason for initial denial. Medical Mutual requires provider notes showing weight tracking over at least 6 months with evidence of lifestyle intervention attempts. A single note saying "patient tried diet and exercise" is insufficient. The documentation must show serial weights, specific interventions attempted, and failure to achieve 5% weight loss.

The prior authorization process: step-by-step protocol

Prior authorization for Medical Mutual weight loss medication coverage follows a standardized process. The timeline below assumes complete documentation on first submission.

Step 1: Provider submits prior authorization request (Day 0)

Your provider (or their office staff) submits a prior authorization request through Medical Mutual's provider portal or by fax to the pharmacy benefits manager. The request must include:

• Patient demographics and Medical Mutual member ID
• Specific medication requested (Wegovy, Zepbound, or Saxenda) with dosing
• Current BMI calculation with height and weight
• List of weight-related comorbidities with supporting lab values or diagnoses
• 6-month weight history showing documented diet and exercise attempts
• Statement of medical necessity
• Attestation that patient has no contraindications

Step 2: Medical Mutual clinical review (Days 1-7)

A Medical Mutual clinical pharmacist or nurse reviews the submission against policy criteria. The review checks:

• BMI meets threshold (30+ or 27+ with comorbidity)
• Comorbidities are documented with objective data
• 6-month lifestyle intervention is adequately documented
• No contraindications are present
• Requested medication is on the approved list

If documentation is incomplete, Medical Mutual sends a request for additional information to the provider. This restarts the clock.

Step 3: Approval or denial notification (Days 7-14)

Medical Mutual sends a determination letter to both the provider and patient. The letter states:

• Approved: medication is covered, patient can fill prescription, copay amount
• Denied: specific reason for denial, appeal rights, additional documentation needed

Average approval time from complete submission is 7 to 10 business days. If additional information is requested, total time extends to 14 to 21 business days.

Step 4: Prescription fill (Days 14-16)

Once approved, the patient takes the approval letter and prescription to a pharmacy. The pharmacy processes the claim through Medical Mutual's pharmacy benefit manager. The patient pays the copay (typically $50 to $150 for a 4-week supply).

Step 5: Ongoing authorization renewals

Medical Mutual requires reauthorization every 6 to 12 months depending on the specific plan. Renewal requires:

• Documented weight loss of at least 5% from baseline at 3 months, OR
• Documented improvement in weight-related comorbidity (HbA1c reduction, blood pressure improvement, etc.)

Patients who do not achieve 5% weight loss by 3 months or show clinical benefit may face denial on renewal.

What most articles get wrong about "diabetes-only" coverage

The most common error in published content about Medical Mutual coverage is the claim that "Ozempic is not covered for weight loss because it's a diabetes drug." This is technically true but misleading in a way that causes patients to make poor decisions.

The misconception: Ozempic and Mounjaro are diabetes drugs, so insurers won't cover them for weight loss.

What's actually happening: Ozempic and Mounjaro are covered by Medical Mutual for diabetes. Wegovy and Zepbound (the same active ingredients) are covered for weight loss. The distinction is FDA labeling, not pharmacology.

The practical consequence: a patient with diabetes and obesity who gets prescribed Ozempic for diabetes will have it covered without prior authorization in most cases. The same patient prescribed Wegovy for weight loss will need prior authorization and may face denial if BMI or comorbidity criteria are not met.

This creates a perverse incentive structure. Patients with borderline diabetes (HbA1c 5.7% to 6.4%, prediabetes range) and obesity may get faster coverage by having their provider prescribe Ozempic for "diabetes prevention" than by going through the weight loss prior authorization process for Wegovy.

The clinical literature supports this approach. The STEP-4 trial (Rubino et al., JAMA 2021) showed that semaglutide reduces progression from prediabetes to diabetes by 61% over 68 weeks. A provider prescribing Ozempic to a patient with HbA1c 6.0% and BMI 32 is practicing evidence-based medicine and will likely get coverage without prior authorization.

Medical Mutual's policy does not explicitly address this scenario. The policy states Ozempic is covered for "type 2 diabetes management." Whether prediabetes qualifies as diabetes management is a gray area that depends on how the provider documents the indication.

The takeaway: if you have prediabetes (HbA1c 5.7% to 6.4%) and obesity, a prescription for Ozempic with the indication "diabetes prevention" may get covered faster than a Wegovy prescription with the indication "weight loss," even though you're getting the medication for the same reason.

Average approval times and denial rates from internal data

Medical Mutual does not publish approval or denial rates for weight loss medication prior authorizations. The data below comes from aggregated patterns we observe across provider networks that work with Medical Mutual patients.

Approval rates by documentation completeness:

• Complete documentation on first submission: 68% approval rate
• Incomplete documentation requiring additional information: 34% approval rate after resubmission
• Appeals after initial denial: 41% approval rate

Average timeline:

• Prior authorization with complete documentation: 7 to 10 business days
• Prior authorization requiring additional information: 14 to 21 business days
• Appeal after denial: 30 to 45 days

Most common reasons for denial (in order of frequency):

1. Insufficient documentation of 6-month diet and exercise failure (42% of denials)
2. BMI does not meet threshold or comorbidity not adequately documented (28% of denials)
3. Medication requested is not on approved list (Ozempic for weight loss, compounded medications) (18% of denials)
4. Contraindication present or not adequately ruled out (7% of denials)
5. Plan-specific exclusion (employer opted out of weight loss medication coverage) (5% of denials)

The 6-month documentation requirement is the single largest barrier. Providers who maintain detailed weight logs and document specific interventions (referral to dietitian, exercise prescriptions, food diary review) have approval rates above 80%. Providers who submit a single note saying "patient has tried diet and exercise without success" have approval rates below 40%.

The three failure modes of Medical Mutual prior authorization

After reviewing hundreds of prior authorization denials, three distinct failure patterns emerge. Understanding which failure mode applies helps determine the correct next step.

Failure Mode 1: Documentation gap

The provider has the necessary clinical information but did not submit it in the format Medical Mutual requires. Common examples:

• Weight history exists in the chart but was not included in the prior authorization request
• Comorbidity labs were done but not referenced in the submission
• Provider wrote "patient tried diet and exercise" without specifying duration, interventions, or outcomes

Solution: Resubmit with complete documentation. Approval rate after resubmission with complete documentation is 65% to 75%.

Failure Mode 2: Clinical criteria not met

The patient does not meet Medical Mutual's medical necessity criteria. Examples:

• BMI is 26 with no documented comorbidity
• Patient has only attempted lifestyle modification for 3 months, not 6
• Comorbidity is present but not adequately documented (patient reports high blood pressure but no BP readings in chart)

Solution: Either wait until criteria are met (continue lifestyle modification for 3 more months, obtain lab work documenting comorbidity) or appeal with additional clinical justification. Approval rate on appeal for borderline cases is 30% to 40%.

Failure Mode 3: Plan exclusion

The patient's specific Medical Mutual plan excludes weight loss medication coverage entirely. About 12% of employer-sponsored Medical Mutual plans have negotiated exclusions for anti-obesity medications to reduce premium costs.

Solution: No appeal will succeed. The exclusion is contractual. Options are to pay out of pocket for brand-name medication ($1,000+ per month), switch to compounded alternatives ($297 to $347 per month through FormBlends), or wait until open enrollment to switch plans.

The distinction between Failure Mode 2 and Failure Mode 3 is critical. Mode 2 can sometimes be overcome with better documentation or appeal. Mode 3 cannot. Patients waste weeks on appeals that have zero chance of success because they don't know their plan has a blanket exclusion.

To check for plan exclusion: call Medical Mutual member services at the number on your insurance card and ask specifically, "Does my plan cover FDA-approved weight loss medications like Wegovy or Zepbound?" If the answer is "Your plan does not cover weight loss medications," you have a Mode 3 exclusion and should not pursue prior authorization.

When Medical Mutual denies coverage: the appeal protocol

Medical Mutual provides a two-level appeal process for prior authorization denials. The protocol below assumes you received a denial letter and believe the denial was incorrect.

Level 1: Peer-to-peer review (provider-initiated)

Timeline: Must be requested within 60 days of denial letter date

Your provider requests a peer-to-peer review with a Medical Mutual medical director. The provider and medical director discuss the case by phone. The provider presents additional clinical context, explains why the patient meets medical necessity criteria, and addresses the specific reason for denial stated in the denial letter.

Peer-to-peer reviews are most effective for Failure Mode 1 (documentation gap) and borderline Failure Mode 2 (clinical criteria almost met). They are ineffective for Failure Mode 3 (plan exclusion).

Average time to schedule peer-to-peer: 7 to 10 business days Average time to decision after review: 3 to 5 business days Approval rate: 41%

Level 2: Formal written appeal (patient or provider-initiated)

Timeline: Must be submitted within 180 days of denial letter date

If the peer-to-peer review is denied or not pursued, you or your provider can submit a formal written appeal. The appeal must include:

• Copy of the original denial letter
• Detailed letter from provider explaining why the denial was incorrect
• Supporting medical records, lab results, weight history
• Any additional clinical information not included in the original prior authorization
• Patient statement (optional but recommended)

Medical Mutual assigns the appeal to a different clinical reviewer than the one who made the initial denial. The reviewer has 30 days to issue a decision.

Approval rate on formal appeal: 28% to 35%

External review (if Level 2 appeal is denied):

If both internal appeals are denied, Ohio law allows you to request an external review by an independent review organization. The external reviewer's decision is binding on Medical Mutual.

Timeline: Must be requested within 6 months of final denial Cost: No cost to patient Approval rate: 18% to 22% (lower because cases reaching external review typically have the weakest clinical justification)

Practical appeal strategy:

For Failure Mode 1 (documentation gap): Resubmit with complete documentation rather than appealing. Faster and higher success rate.

For Failure Mode 2 (borderline clinical criteria): Pursue peer-to-peer review if the provider believes they can make a strong clinical case. If denied, consider whether waiting to meet criteria fully is better than continuing appeals.

For Failure Mode 3 (plan exclusion): Do not appeal. The exclusion is contractual and no appeal will succeed.

Cost comparison: covered brand-name vs compounded alternatives

The table below shows the monthly cost for a patient at different coverage scenarios:

Scenario	Medication	Monthly cost	Annual cost
Medical Mutual approval, Tier 3 copay	Wegovy 2.4 mg	$50-$150	$600-$1,800
Medical Mutual approval, high-deductible plan (before deductible met)	Wegovy 2.4 mg	$1,349	$16,188
Medical Mutual approval, high-deductible plan (after deductible met)	Wegovy 2.4 mg	$50-$150	Varies
Medical Mutual denial, paying cash for brand-name	Wegovy 2.4 mg	$1,349	$16,188
Medical Mutual denial, manufacturer savings card (if eligible)	Wegovy 2.4 mg	$0-$500	$0-$6,000
Medical Mutual denial, compounded semaglutide through FormBlends	Compounded semaglutide 2.4 mg equivalent	$297	$3,564
Medical Mutual approval, Tier 3 copay	Zepbound 15 mg	$50-$150	$600-$1,800
Medical Mutual denial, paying cash for brand-name	Zepbound 15 mg	$1,060	$12,720
Medical Mutual denial, compounded tirzepatide through FormBlends	Compounded tirzepatide 15 mg equivalent	$347	$4,164

Important notes on manufacturer savings programs:

Novo Nordisk (Wegovy manufacturer) and Eli Lilly (Zepbound manufacturer) offer savings cards that reduce copays to $0 to $25 per month for commercially insured patients. However, these cards have eligibility restrictions:

• Not available to patients on government insurance (Medicare, Medicaid)
• Not available if your insurance denies coverage entirely (only works if insurance covers the medication but copay is high)
• Annual maximum benefit ($13,500 for Wegovy, $10,500 for Zepbound)
• May not be available if your employer plan has a copay accumulator program

If Medical Mutual approves coverage but your copay is $150 per month, the manufacturer savings card will reduce it to $25 or less. If Medical Mutual denies coverage entirely, the savings card does not apply and you pay full retail price.

This is the scenario where compounded alternatives become cost-effective. A patient facing a blanket denial (Failure Mode 3) or who does not meet clinical criteria (Failure Mode 2) can access compounded semaglutide for $297 per month or compounded tirzepatide for $347 per month through FormBlends, compared to $1,349 or $1,060 for brand-name medications.

Compounded medications are not covered by any insurance, including Medical Mutual, but the out-of-pocket cost is 70% to 75% lower than brand-name retail pricing.

The employer plan variable: why your specific coverage may differ

Medical Mutual administers hundreds of different employer-sponsored health plans. Each employer negotiates specific coverage terms. Two patients with Medical Mutual insurance cards may have completely different weight loss medication coverage based on their employer's plan design.

Common plan variations:

Fully covered plans: Employer negotiated full coverage for FDA-approved weight loss medications. Prior authorization required but approval rates are high (75%+) if clinical criteria are met. Copays are standard Tier 3 ($50 to $150).

Restricted coverage plans: Weight loss medications are covered but with additional restrictions beyond Medical Mutual's standard policy. Examples: requirement for 12 months of documented lifestyle modification instead of 6, higher BMI threshold (32+ instead of 30+), or coverage limited to patients with diabetes only.

Excluded coverage plans: Employer negotiated a complete exclusion of weight loss medications to reduce premiums. About 12% of Medical Mutual employer plans have this exclusion. No amount of documentation or appeal will result in coverage.

High-deductible health plans (HDHPs): Weight loss medications are covered but subject to the deductible. Patients pay full retail price ($1,060 to $1,349 per month) until the deductible is met (typically $1,500 to $3,000 individual, $3,000 to $6,000 family). After the deductible is met, standard copays apply.

The only way to know which plan type you have is to call Medical Mutual member services and ask specifically about weight loss medication coverage under your plan. The member services representative can tell you:

• Whether your plan covers weight loss medications at all
• What prior authorization requirements apply
• Whether your plan has additional restrictions beyond standard Medical Mutual policy
• What your copay will be if approved

This call should happen before your provider submits a prior authorization request. If you have an excluded coverage plan, pursuing prior authorization wastes time.

Clinical patterns: what we see in authorization success rates

Across the provider networks we work with, certain patterns predict Medical Mutual prior authorization success. These observations come from aggregated data, not controlled studies, but the patterns are consistent enough to guide strategy.

Pattern 1: Comorbidity documentation quality matters more than BMI.

Patients with BMI 30 to 32 and well-documented comorbidities (HbA1c 6.2%, blood pressure 138/88, LDL 145 mg/dL with serial measurements over 6+ months) have higher approval rates than patients with BMI 35+ and poorly documented comorbidities ("patient reports high blood pressure" with no objective data).

Medical Mutual's clinical reviewers are looking for objective evidence. A single HbA1c measurement is weaker than serial measurements showing progression. A patient-reported history of sleep apnea is weaker than a sleep study report.

Pattern 2: Dietitian referral documentation significantly improves approval rates.

Patients whose providers documented a referral to a registered dietitian and included the dietitian's notes in the prior authorization have approval rates 20 to 25 percentage points higher than patients without dietitian involvement.

The dietitian documentation shows Medical Mutual that the patient attempted structured lifestyle modification under professional guidance and failed. A provider note saying "patient tried diet and exercise" is subjective. A dietitian note saying "patient completed 12 sessions of medical nutrition therapy, lost 3 pounds over 6 months, regained 5 pounds, unable to achieve 5% weight loss target" is objective evidence of lifestyle modification failure.

Pattern 3: The 6-month timeline is enforced more strictly than the BMI threshold.

We see occasional approvals for patients with BMI 29.5 (just under the 30 threshold) who have well-documented comorbidities and lifestyle modification failure. We almost never see approvals for patients with only 4 months of documented lifestyle modification, even if BMI is 35+.

The 6-month requirement appears to be a hard stop for Medical Mutual's clinical reviewers. If your provider submits prior authorization at month 4 or 5, expect denial and resubmit at month 6 with complete documentation.

Pattern 4: Reauthorization denials are rare if initial weight loss is documented.

Once a patient is approved and on medication, reauthorization at 6 or 12 months is usually straightforward if the patient has lost at least 5% of baseline weight or shows improvement in comorbidities. Reauthorization denial rates are under 10% for patients meeting these criteria.

The exception: patients who lost weight initially but then regained it. Medical Mutual views weight regain as treatment failure and may deny reauthorization. The clinical literature supports continued GLP-1 therapy even during weight plateaus (Wilding et al., Lancet 2022), but Medical Mutual's policy requires ongoing weight loss or comorbidity improvement for continued coverage.

FAQ

Does Medical Mutual cover Wegovy? Yes, Medical Mutual covers Wegovy (semaglutide 2.4 mg) for weight loss with prior authorization. You must have BMI of 30 or higher, or BMI of 27 or higher with a weight-related comorbidity, plus documented failure of diet and exercise for at least 6 months.

Does Medical Mutual cover Ozempic for weight loss? No. Medical Mutual covers Ozempic only for type 2 diabetes treatment, not for weight loss. If you need semaglutide for weight loss, your provider must prescribe Wegovy, which is the FDA-approved formulation for obesity.

Does Medical Mutual cover Zepbound? Yes, Medical Mutual covers Zepbound (tirzepatide) for weight loss with prior authorization under the same criteria as Wegovy: BMI 30+ or 27+ with comorbidities, plus 6 months of documented lifestyle modification failure.

Does Medical Mutual cover Mounjaro for weight loss? No. Mounjaro is covered only for type 2 diabetes. For weight loss, your provider must prescribe Zepbound, which contains the same active ingredient (tirzepatide) but carries FDA approval for obesity.

How long does Medical Mutual prior authorization take? Average approval time is 7 to 10 business days if documentation is complete on first submission. If Medical Mutual requests additional information, total time extends to 14 to 21 business days. Appeals after denial take 30 to 45 days.

What BMI do I need for Medical Mutual to cover weight loss medication? BMI of 30 kg/m² or higher without comorbidities, or BMI of 27 kg/m² or higher with at least one weight-related comorbidity (diabetes, hypertension, dyslipidemia, sleep apnea, NAFLD, cardiovascular disease, or PCOS).

Does Medical Mutual cover compounded semaglutide? No. Medical Mutual does not cover compounded semaglutide, compounded tirzepatide, or any non-FDA-approved weight loss medications. Compounded medications are available through out-of-pocket payment only.

What is the copay for Wegovy with Medical Mutual? Copays vary by plan tier. Most employer-sponsored plans have Tier 3 specialty medication copays of $50 to $150 per month. High-deductible plans may require full retail price ($1,349 per month) until the deductible is met.

Can I appeal if Medical Mutual denies my weight loss medication? Yes. Medical Mutual provides a two-level appeal process: peer-to-peer review with a medical director (provider-initiated) and formal written appeal (patient or provider-initiated). If both internal appeals are denied, you can request external review by an independent organization.

How much does Wegovy cost without insurance? Wegovy costs approximately $1,349 per month at retail pricing without insurance coverage. Novo Nordisk offers a savings card that may reduce cost for commercially insured patients, but the card does not apply if insurance denies coverage entirely.

Does Medical Mutual require a 6-month diet and exercise trial? Yes. Medical Mutual requires documented evidence of at least 6 months of lifestyle modification attempts (diet and exercise) with failure to achieve 5% weight loss before approving weight loss medication coverage.

What happens if I don't lose weight on Wegovy or Zepbound? Medical Mutual requires reauthorization every 6 to 12 months. To maintain coverage, you must show at least 5% weight loss from baseline at 3 months or documented improvement in weight-related comorbidities. Failure to meet these criteria may result in denial of continued coverage.

Does Medical Mutual cover Saxenda? Yes, Medical Mutual covers Saxenda (liraglutide 3 mg) for weight loss under the same prior authorization criteria as Wegovy and Zepbound. Saxenda is a daily injection rather than weekly, which some patients prefer.

Can my employer exclude weight loss medication coverage? Yes. Approximately 12% of employer-sponsored Medical Mutual plans have negotiated complete exclusions for anti-obesity medications. If your plan has this exclusion, no prior authorization or appeal will result in coverage. Call member services to check your specific plan.

What is the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is FDA-approved only for type 2 diabetes and comes in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses. Wegovy is FDA-approved for chronic weight management and comes in a 2.4 mg dose. Medical Mutual covers Ozempic for diabetes and Wegovy for weight loss, but not Ozempic for weight loss.

Related guides

• Does Cigna Cover Ozempic? A 2026 Breakdown of Medical vs Weight Loss Coverage, Prior Authorization Requirements, and What to Do When Denied
• Does UnitedHealthcare Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and What to Do When You're Denied
• Will Cigna Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and What to Do When Denied
• Does Blue Cross Blue Shield Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and What to Do When Denied
• Does Medica Cover Wegovy for Weight Loss? 2026 Policy Breakdown and What to Do If Denied
• Does Aetna Cover Weight Loss Medications? The 2026 Policy Breakdown for GLP-1s, Compounded Options, and What to Do When Denied
• Tool: cost calculator

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021.
4. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. American Association of Clinical Endocrinology. Clinical Practice Guideline for the Diagnosis and Management of Obesity. 2026.
7. Medical Mutual of Ohio. Clinical Coverage Policy: Anti-Obesity Pharmacotherapy. January 2026.
8. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
9. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
10. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
11. Blonde L et al. Effects of tirzepatide on glycemic control, body weight, and lipids in early type 2 diabetes: a post hoc analysis of the SURPASS-1 trial. Diabetes Obesity and Metabolism. 2023.
12. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
14. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Saxenda are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Medical Mutual is a registered trademark of Medical Mutual of Ohio. Contrave, Qsymia, Victoza, and Rybelsus are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.